Actinium Pharmaceuticals
ATNM
43 hedge funds and large institutions have $4.24M invested in Actinium Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 9 reducing their positions, and 6 closing their positions.
24% more capital invested
Capital invested by funds: $3.42M → $4.24M (+$817K)
0% more funds holding
Funds holding: 43 → 43 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
0.01% less ownership
Funds ownership: 0.25% → 0.25% (-0.01%)
33% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$651K |
| 2 |
Charles Schwab
San Francisco,
California
|
+$42.7K |
| 3 |
OC
Oppenheimer & Co
New York
|
+$38.2K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$31.5K |
| 5 |
Renaissance Technologies
New York
|
+$30.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DAM
DLD Asset Management
New York
|
-$624K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$63K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$36K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$28.9K |
| 5 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$22K |
ATNM Hedge Fund Activity: Q1 2019 in Review
43 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q1 2019, worth a combined $4.24M — up 24% from $3.42M a quarter earlier.
Fund positioning in ATNM was balanced in Q1 2019: 6 funds opened new positions, 6 closed out, 6 added to existing stakes and 9 trimmed.
The largest buyer was Vanguard Group, adding an estimated $651K. The largest seller was DLD Asset Management, cutting an estimated $624K.
- 43 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q1 2019, unchanged from Q4 2018.
- Funds reported $4.24M of Actinium Pharmaceuticals stock for Q1 2019, up 24% quarter-over-quarter.
- 6 funds opened new Actinium Pharmaceuticals positions in Q1 2019 and 6 closed out, a net change of 0 holders.
- The largest Actinium Pharmaceuticals buyer in Q1 2019 was Vanguard Group, an estimated $651K added.
- The largest Actinium Pharmaceuticals seller in Q1 2019 was DLD Asset Management, an estimated $624K sold.
Based on aggregated 13F filings for Q1 2019.